Could 1 Tiny Biotech Topple Vertex Pharmaceuticals’ Cystic Fibrosis Empire?
Vertex Pharmaceuticals (VRTX +2.10%) has dominated the market for cystic fibrosis (CF) medicines since it earned approval for its first drug in this niche in 2012. To this day, most of the company’s revenue comes from its CF franchise. In the second quarter, Vertex posted $3.33 billion in revenue, representing a 12% year-over-year increase. CF-related…